Lamotrigine Extended-Release In Elderly Patients With Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Epilepsy
Interventions
DRUG

Lamotrigine

Open-label

Trial Locations (63)

4074

GSK Investigational Site, Scarborough

11516

GSK Investigational Site, Cedarhurst

12308

GSK Investigational Site, Schenectady

14642

GSK Investigational Site, Rochester

15240

GSK Investigational Site, Pittsburgh

18960

GSK Investigational Site, Sellersville

19102

GSK Investigational Site, Philadelphia

19140

GSK Investigational Site, Philadelphia

19713

GSK Investigational Site, Newark

23298

GSK Investigational Site, Richmond

30024

GSK Investigational Site, Suwanee

30309

GSK Investigational Site, Atlanta

30322

GSK Investigational Site, Atlanta

32082

GSK Investigational Site, Ponte Vedra Beach

32224

GSK Investigational Site, Jacksonville

32266

GSK Investigational Site, Jacksonville

32610

GSK Investigational Site, Gainesville

32901

GSK Investigational Site, Melbourne

33136

GSK Investigational Site, Miami

34233

GSK Investigational Site, Sarasota

37232

GSK Investigational Site, Nashville

38018

GSK Investigational Site, Cordova

38139

GSK Investigational Site, Germantown

38401

GSK Investigational Site, Columbia

40202

GSK Investigational Site, Louisville

43210

GSK Investigational Site, Columbus

43614

GSK Investigational Site, Toledo

46256

GSK Investigational Site, Indianapolis

46805

GSK Investigational Site, Fort Wayne

49684

GSK Investigational Site, Traverse City

53215

GSK Investigational Site, Milwaukee

53226

GSK Investigational Site, Milwaukee

53715

GSK Investigational Site, Madison

55102

GSK Investigational Site, Saint Paul

55422

GSK Investigational Site, Minneapolis

62702

GSK Investigational Site, Springfield

63017

GSK Investigational Site, Chesterfield

64111

GSK Investigational Site, Kansas City

67214

GSK Investigational Site, Wichita

73112

GSK Investigational Site, Oklahoma City

75214

GSK Investigational Site, Dallas

75230

GSK Investigational Site, Dallas

76508

GSK Investigational Site, Temple

77030

GSK Investigational Site, Houston

80524

GSK Investigational Site, Fort Collins

83702

GSK Investigational Site, Boise

85003

GSK Investigational Site, Phoenix

85013

GSK Investigational Site, Phoenix

85234

GSK Investigational Site, Gilbert

85340

GSK Investigational Site, Litchfield Park

89014

GSK Investigational Site, Henderson

90073

GSK Investigational Site, Los Angeles

91106

GSK Investigational Site, Pasadena

92618

GSK Investigational Site, Irvine

92835

GSK Investigational Site, Fullteron

93710

GSK Investigational Site, Fresno

98310

GSK Investigational Site, Bremerton

35294-0021

GSK Investigational Site, Birmingham

01805

GSK Investigational Site, Burlington

01747

GSK Investigational Site, Hopedale

08103

GSK Investigational Site, Camden

07103

GSK Investigational Site, Newark

07901

GSK Investigational Site, Summit

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY